Report
Keywords - Next Generation, Inhibitors, Stimulators Market, Roots Analysis,
Report
Therapies targeting
novel inhibitory and stimulatory immune checkpoints have been shown to possess
substantial therapeutic potential, both as monotherapies and in combination
with other interventions, across multiple disease interventions
Roots Analysis is pleased to
announce the publication of its recent study, titled, “Next Generation Immune
Checkpoint Inhibitors and Stimulators Market, 2020-2030.”
The report features an extensive study of the
current market landscape, offering an informed opinion on the likely adoption
of these therapies over the next decade. It features an in-depth analysis,
highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:
§ A detailed assessment
of the current market landscape of drug developers engaged in the development
of next generation immune checkpoint modulators.
§ A detailed analysis
of more than 590 completed, ongoing and planned clinical studies of next
generation immune checkpoint inhibitors and stimulators.
§ Detailed profiles of
developers of next generation immune checkpoint modulators (shortlisted
on the basis of the number of pipeline products).
§ An in-depth analysis
of more than 490 grants that have been awarded to research institutes engaged
in next generation immune checkpoint therapy-related projects.
§ An analysis of the
partnerships that have been established in this domain, in the recent past.
§ A competitiveness
analysis of biological targets, featuring insightful pictorial summaries and
representations.
§ An analysis of the initiatives
of big biopharma players engaged in this domain.
§ A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
To request for sample
report – https://www.rootsanalysis.com/reports/303/request-sample.html
- Target Disease Indication
§ Breast Cancer
§ Chronic Lymphocytic
Leukemia
§ Colorectal Cancer
§ Head and Neck Cancer
§ Lung Cancer
§ Lupus Nephritis
§ Melanoma
§ Multiple Myeloma
§ Primary Sjögren's
Syndrome
§ Others
- Target Immune Checkpoint
§ B7-H3
§ CD38
§ CD40
§ CD47
§ Others
- Mechanism of Action
§ Inhibitory
§ Stimulatory
- Therapeutic Modality
§ Monoclonal Antibody
§ Small Molecule
- Type of Therapy
§ Monotherapy
§ Combination Therapy
- Route of Administration
§ Intravenous
§ Subcutaneous
§ Others
- Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific and the
Rest of the World
Key
companies covered in the report
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Other Recent Offerings
1. Neoantigen Targeted
Therapies Market, 2019-2030
2. Bispecific Antibody
Therapeutics Market (4th Edition), 2019-2030
3. Global Stem Cells
Market: Focus on Clinical Therapies, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest
growing market research companies, sharing fresh and independent perspectives
in the bio-pharmaceutical industry. The in-depth research, analysis and
insights are driven by an experienced leadership team which has gained many
years of significant experience in this sector. If you’d like help with your
growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private
Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis